HER2-Targeted Therapies Summit 2022

Temas de la conferencia
The momentum in anti-HER2 drug development is exploding:

Outcomes for HER2-expressing breast cancer are patients constantly improving; diagnostics, trial design and innovative drug design are at an all-time high; complementing the newly accessible HER2 'low' space and wider range of tumor indications; the last year has given us more progress in HER2-targeted therapies than ever before.

Organizador profesional (PCO)
Hanson Wade

Observaciones
Speakers: Cecile Geuijen Chief Scientific Officer and Vice President - Oncology, Merus, Shane Olwill Chief Development Officer, Senior Vice President and Head of Translational Science, Pieris Pharmaceuticals and more.

https://go.evvnt.com/1003520-2?pid=4832

Ms. Ellie Saunders